American Journal of Transplantation

Article	Citations
Morning Administration Enhances Humoral Response to SARS-CoV-2 Vaccination in Kidney Transplant Recipients	875376689
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter	612
The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection	419
COVID-19 in solid organ transplant recipients: A single-center case series from Spain	324
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium	286
Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus	273
OPTN/SRTR 2019 Annual Data Report: Kidney	273
Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression	234
OPTN/SRTR 2019 Annual Data Report: Liver	228
OPTN/SRTR 2020 Annual Data Report: Liver	205
Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?	200
First clinical-grade porcine kidney xenotransplant using a human decedent model	196
COVID-19 in kidney transplant recipients	189
Early impact of COVID-19 on transplant center practices and policies in the United States	187
Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients	186
Decreased influenza activity during the COVID-19 pandemic—United States, Australia, Chile, and South Africa, 2020	186
OPTN/SRTR 2020 Annual Data Report: Kidney	185
Is COVID-19 infection more severe in kidney transplant recipients?	174
COVID-19: A global transplant perspective on successfully navigating a pandemic	170
COVID-19 in kidney transplant recipients	154
Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: Potential role of ferroptosis	143
COVID-19 in transplant recipients: The Spanish experience	135
Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation	131
Coronavirus disease 2019: Implications of emerging infections for transplantation	128
The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs	123

OPTN/SRTR 2019 Annual Data Report: Lung	122
SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study	120
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients	116
Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation–Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation	114
Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients	110
Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: A cohort study	110
A change of heart: Preliminary results of the US 2018 adult heart allocation revision	109
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients	107
Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients	107
OPTN/SRTR 2020 Annual Data Report: Heart	106
Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing	103
Impact of COVID-19 in solid organ transplant recipients	95
COVID-19 in posttransplant patients—report of 2 cases	94
COVID-19 vaccination intent, perceptions, and reasons for not vaccinating among groups prioritized for early vaccination — United States, September and December 2020	93
Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients	92
First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study	91
Maintaining the permanence principle for death during in situ normothermic regional perfusion for donation after circulatory death organ recovery: A United Kingdom and Canadian proposal	89
OPTN/SRTR 2019 Annual Data Report: Heart	89
Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions — United States, January–May 2020	89
Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve	89
Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients	87
Long-term kidney transplant graft survival—Making progress when most needed	84
Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept	82
Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach	82
Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States	81
High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury	81
Liver transplantation for critically ill cirrhotic patients: Stratifying utility based on pretransplant factors	81
Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review	80
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave	79
Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?	77
Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients	76
Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients	75
Decline in child vaccination coverage during the COVID-19 pandemic — Michigan Care Improvement Registry, May 2016-May 2020	75
OPTN/SRTR 2020 Annual Data Report: Lung	74
A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned	74
Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience	74
Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study	73
Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States	73
COVID-19 in Spain: Transplantation in the midst of the pandemic	73
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine	70
Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients	70
Use of SARS-CoV-2-infected deceased organ donors: Should we always “just say no?”	69
Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report	68
SARS Cov-2 infection in a renal-transplanted patient: A case report	68
Abdominal normothermic regional perfusion in controlled donation after circulatory determination of death liver transplantation: Outcomes and risk factors for graft loss	67
Fatal outcome in a liver transplant recipient with COVID-19	67
Ten years of donor-derived disease: A report of the disease transmission advisory committee	67
Use of tocilizumab in kidney transplant recipients with COVID-19	66
Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients	66
Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients	65

Immunosuppression drug-related and clinical manifestation of Coronavirus disease 2019: A therapeutical hypothesis	64
Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies	64
PD-1 inhibitor as bridge therapy to liver transplantation?	63
Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes	63
COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination	63
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement	63
COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities	61
COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients	61
Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques	61
Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine	60
Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients	60
Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient	59
In-depth virological assessment of kidney transplant recipients with COVID-19	59
Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases	59
Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—A prospective observational trial	58
A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients	58
COVID-19 in elderly kidney transplant recipients	58
Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients	58
Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study	58
Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients	58
Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients	57
The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy	57
Sequential hypothermic and normothermic machine perfusion enables safe transplantation of high-risk donor livers	57
Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report	56
Coronavirus disease 2019 and transplantation: A view from the inside	55
Hypothermic oxygenated perfusion in extended criteria donor liver transplantation—A randomized clinical trial	55
Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic	55
Organ donation during the COVID-19 pandemic	53
Clinical outcomes and serologic response in solid organ transplant recipients with COVID-19: A case series from the United States	53
Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation	53
Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation	52
Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?	52
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge	52
Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort	52
Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients	51
COVID-19 in lung transplant recipients: A single center case series from New York City	51
Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic	51
A case of coronavirus disease 2019–infected liver transplant donor	51
A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action	51
Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants	51
First case of COVID-19 in a kidney transplant recipient treated with belatacept	50
Consensus conference on heart-kidney transplantation	49
Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020–2021	49
Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry	49
Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2–positive donors	49
A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation	49
OPTN/SRTR 2021 Annual Data Report: Kidney	49
Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?	48
COVID-19 in lung transplant recipients: A multicenter study	48
A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors	48
Immunosuppressive therapy maintenance in a kidney transplant recipient with SARS-CoV-2 pneumonia: A case report	48
OPTN/SRTR 2021 Annual Data Report: Liver	46
Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study	46
RNA interference therapeutics in organ transplantation: The dawn of a new era	45
SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients	45
Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency	45
Substituting imputation of HLA antigens for high-resolution HLA typing: Evaluation of a multiethnic population and implications for clinical decision making in transplantation	45
Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study	45
Improved short-term outcomes of kidney transplants in controlled donation after the circulatory determination of death with the use of normothermic regional perfusion	44
Novel delivery of cellular therapy to reduce ischemia reperfusion injury in kidney transplantation	44
First-in-human use of a marine oxygen carrier (M101) for organ preservation: A safety and proof-of-principle study	44
OPTN/SRTR 2020 Annual Data Report: Pancreas	44
An international comparison of deceased donor kidney utilization: What can the United States and the United Kingdom learn from each other?	44
Neighborhood socioeconomic deprivation is associated with worse patient and graft survival following pediatric liver transplantation	44
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics	44
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement	43
Normothermic kidney perfusion: An overview of protocols and strategies	42
Evidence for the alloimmune basis and prognostic significance of Borderline T cell–mediated rejection	42
Allograft infiltration and meningoencephalitis by SARS-CoV-2 in a pancreas-kidney transplant recipient	42
Dialysis facility referral and start of evaluation for kidney transplantation among patients treated with dialysis in the Southeastern United States	42
Greater complexity and monitoring of the new Kidney Allocation System: Implications and unintended consequences of concentric circle kidney allocation on network complexity	41
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder	41
Cyclosporine and COVID-19: Risk or favorable?	41
Prolonged preservation by hypothermic machine perfusion facilitates logistics in liver transplantation: A European observational cohort study	41
First World Consensus Conference on pancreas transplantation: Part II – recommendations	41
Early liver transplantation after COVID-19 infection: The first report	41
Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak — United States, December 31, 2019–February 4, 2020	40
mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients	40
CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept	40
OPTN/SRTR 2019 Annual Data Report: Pancreas	40

Spanish experience with heart transplants from controlled donation after the circulatory determination of death using thoraco-abdominal normothermic regional perfusion and cold storage	40
Ethical and logistical concerns for establishing NRP-cDCD heart transplantation in the United States	40
White paper on antimicrobial stewardship in solid organ transplant recipients	40
Donor and transplant candidate selection for solid organ transplantation during the COVID-19 pandemic	40
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation	40
Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients	40
A familial cluster, including a kidney transplant recipient, of Coronavirus Disease 2019 (COVID-19) in Wuhan, China	40
Outcome of liver transplantation with grafts from brain-dead donors treated with dual hypothermic oxygenated machine perfusion, with particular reference to elderly donors	40
Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients	39
COVID-19 in pediatric kidney transplantation: The Improving Renal Outcomes Collaborative	39
Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection	39
Obesity, transplantation, and bariatric surgery: An evolving solution for a growing epidemic	39
Meta-analysis and meta-regression of outcomes for adult living donor liver transplantation versus deceased donor liver transplantation	39
Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic	39
Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic	39
Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients	39
First-in-man controlled rewarming and normothermic perfusion with cell-free solution of a kidney prior to transplantation	38
COVID-19 in a high-risk dual heart and kidney transplant recipient	38
Navigating the COVID-19 pandemic: Initial impacts and responses of the Organ Procurement and Transplantation Network in the United States	38
Dismantling structural racism as a root cause of racial disparities in COVID-19 and transplantation	38
Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial	38
Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma	38
Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021	37
The negative impact of T cell–mediated rejection on renal allograft survival in the modern era	37
New French heart allocation system: Comparison with Eurotransplant and US allocation systems	37
Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection	37
Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020	36
In situ multiplex immunofluorescence analysis of the inflammatory burden in kidney allograft rejection: A new tool to characterize the alloimmune response	36
Initial lung transplantation experience with uncontrolled donation after cardiac death in North America	36
Prevalence of frailty among kidney transplant candidates and recipients in the United States: Estimates from a National Registry and Multicenter Cohort Study	36
Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor	36
Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia	36
Lysis of cold-storage-induced microvascular obstructions for ex vivo revitalization of marginal human kidneys	36
The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era	36
Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients	36
Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients	36
Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota	36
Cytokine absorption during human kidney perfusion reduces delayed graft function–associated inflammatory gene signature	36
An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients	35
Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options	35
Racial disparities in preemptive waitlisting and deceased donor kidney transplantation: Ethics and solutions	35
Guidelines for standardized nomenclature and reporting in uterus transplantation: An opinion from the United States Uterus Transplant Consortium	35
Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose	35
Negative immune responses to two-dose mRNA COVID-19 vaccines in renal allograft recipients assessed with simple antibody and interferon gamma release assay cellular monitoring	35
T cell and antibody responses to SARS-CoV-2: Experience from a French transplantation and hemodialysis center during the COVID-19 pandemic	35
Reversing donor-specific antibody responses and antibody-mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients	35
Extracellular vesicles for treatment of solid organ ischemia–reperfusion injury	34
Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial	34
COVID-19 in hospitalized lung and non-lung solid organ transplant recipients: A comparative analysis from a multicenter study	34
Banff Digital Pathology Working Group: Going digital in transplant pathology	34
Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation	34
Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report	34
Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection	33
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era	33
Revisiting the changes in the Banff classification for antibody-mediated rejection after kidney transplantation	33
Ethical review of COVID-19 vaccination requirements for transplant center staff and patients	33
Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study	33
COVID-19 in lung transplant patients: A case series	32
Utilization and outcomes of deceased donor SARS-CoV-2–positive organs for solid organ transplantation in the United States	32
Response to American College of Physician’s statement on the ethics of transplant after normothermic regional perfusion	32
Mechanisms of organ transplant injury mediated by B cells and antibodies: Implications for antibody-mediated rejection	32
Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients	32
Brief O2 uploading during continuous hypothermic machine perfusion is simple yet effective oxygenation method to improve initial kidney function in a porcine autotransplant model	32
Molecular phenotyping of rejection-related changes in mucosal biopsies from lung transplants	32
Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab	32
Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region	32
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update	31
Mild COVID-19 in a pediatric renal transplant recipient	31
OPTN/SRTR 2021 Annual Data Report: Lung	31
Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses	30
OPTN/SRTR 2019 Annual Data Report: Intestine	30
Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020	30
Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort	30
Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning	30
Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely	30
Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity	30
Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members — Chicago, Illinois, December 2020–March 2021	30
Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients	30
Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience	30
Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients	30
The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study	30
A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation	29
Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept	29
Two distinct cases with COVID-19 in kidney transplant recipients	29
Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: A 2-year review of the OPTN’s allocation policy	29
The impact of multi-organ transplant allocation priority on waitlisted kidney transplant candidates	29
COVID-19 in solid organ transplant recipients: A national cohort study from Sweden	29
Shielding islets with human amniotic epithelial cells enhances islet engraftment and revascularization in a murine diabetes model	29
Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes	28
Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19	28
Immunosuppressive therapy after solid organ transplantation and the gut microbiota: Bidirectional interactions with clinical consequences	28
Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study	28
Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin	28
Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation	28
HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV	28